These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34430574)

  • 1. Cost-effectiveness analysis of hemodialysis plus hemoperfusion versus hemodialysis alone in adult patients with end-stage renal disease in China.
    Wang H; Jin H; Cheng W; Qin X; Luo Y; Liu X; Fu Y; Jiang G; Lu W; Jin C; Pennington M
    Ann Transl Med; 2021 Jul; 9(14):1133. PubMed ID: 34430574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
    Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
    BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose hemodialysis versus conventional in-center hemodialysis: a cost-utility analysis from a UK payer perspective.
    Liu FX; Treharne C; Arici M; Crowe L; Culleton B
    Value Health; 2015 Jan; 18(1):17-24. PubMed ID: 25595230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol.
    Lu W; Jiang GR;
    BMJ Open; 2018 Jul; 8(7):e022169. PubMed ID: 30056391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis.
    Zhou W; Liang Z; Lou X; Wang N; Liu X; Li R; Pai P
    Front Pharmacol; 2024; 15():1283922. PubMed ID: 38469404
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?
    Yousefi M; Rezaei S; Hajebrahimi S; Falsafi N; Keshvari-Shad F
    BMC Nephrol; 2024 Mar; 25(1):85. PubMed ID: 38448887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Outcomes of Hemoperfusion and Hemodialysis versus Hemodialysis in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
    Cheng W; Luo Y; Wang H; Qin X; Liu X; Fu Y; Ronco C
    Blood Purif; 2022; 51(3):213-225. PubMed ID: 33971651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
    Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
    Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of High Dose Hemodialysis in Comparison to Conventional In-Center Hemodialysis in the Netherlands.
    Beby AT; Cornelis T; Zinck R; Liu FX
    Adv Ther; 2016 Nov; 33(11):2032-2048. PubMed ID: 27664108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
    Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
    Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease.
    Assanatham M; Pattanaprateep O; Chuasuwan A; Vareesangthip K; Supasyndh O; Lumpaopong A; Susantitaphong P; Limkunakul C; Ponthongmak W; Chaiyakittisopon K; Thakkinstian A; Ingsathit A
    BMC Health Serv Res; 2022 Nov; 22(1):1384. PubMed ID: 36411422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
    Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
    Peng Z; Hou X; Huang Y; Xie T; Hua X
    BMC Cancer; 2020 Oct; 20(1):990. PubMed ID: 33050905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.